Daniel Monakier

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto, Artur Oręziak, Roberto Barriales‐Villa et al. · The Lancet · 2020 · 1.2K citations · Full text

Medicine, Cardiology, Pharmacotherapy +6

Enlarged Left Atrial Volume in Hypertrophic Cardiomyopathy: A Marker for Disease Severity

Hua Yang, Anna Woo, Daniel Monakier et al. · Journal of the American Society of Echocardiography · 2005 · 159 citations

Medicine, Cardiology, Clinical Cardiology +8

Right ventricular pacing increases tricuspid regurgitation grade regardless of the mechanical interference to the valve by the electrode

M. Vaturi, J. Kusniec, Y. Shapira et al. · European Journal of Echocardiography · 2010 · 109 citations

Medicine, Cardiology, Internal Medicine +13

Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy: Figure 1

A Woo, Daniel Monakier, Louise Harris et al. · Heart · 2007 · 77 citations · Full text

Medicine, Cardiology, Internal Medicine +12

Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy

Daniel Monakier, Anna Woo, Timothy Puri et al. · The American Journal of Cardiology · 2004 · 45 citations

Medicine, Cardiology, Radiology +16